Departed
Jeff Schwaneke
Director
AGL ·
agilon health, inc.
In connection with his appointment, Mr. Schwaneke will resign from the agilon health, inc. Board of Directors.
Ready 8-Ks
50
Latest filing
August 5, 2026, 4:07 PM ET
Top materiality
0.90
Event mix
earnings ×19 · leadership ×14 · other_material ×10
Sentiment
10 pos · 11 neg · 29 neu
Latest earnings
reported 2026-Q1
Executive change
recent →
Recent 8-K filings for AGL
Highest-materiality recent filing
agilon health cuts 2023 medical margin guidance by ~$110M; withdraws 2026 outlook
- 2023 medical margin guidance lowered to $340M-$360M from $455M-$470M, a ~$110M reduction.
- 2023 Adjusted EBITDA guidance revised to loss of $55M-$69M from prior profit of $6M-$18M.
-
agilon health Q2 net income $18M vs loss; raises FY2026 guidance
Total revenue $1.49B (+7% YoY); net income $18M vs net loss $104M in Q2 2025.
-
CTO Girish Venkatachaliah departs Aug 1; will provide transition consulting through Dec 31, 2026.
-
agilon health annual meeting votes; all three proposals approved
Diana McKenzie, Karen McLoughlin, Ronald Williams elected Class II directors through 2029.
-
Q1 net income $49M vs $12M YoY; Adjusted EBITDA $54M vs $21M; medical margin $149M vs $128M.
-
agilon health appoints Tim O'Rourke as CEO, effective May 7, 2026
Tim O'Rourke appointed CEO/President, effective May 7, 2026; joins Board as Class III director.
-
agilon health completes 1-for-25 reverse stock split effective March 30, 2026
Ratio set at 1-for-25; approved by stockholders at March 17, 2026 special meeting.
-
agilon health to effect 1-for-25 reverse stock split on March 30, 2026 to maintain NYSE listing
Stockholders approved reverse split at special meeting on March 17; votes were 356,574,789 for, 6,187,388 against, 365,864 abstained.
-
agilon health Q4 net loss $189M, revenue $1.57B; 2026 guidance Adj EBITDA breakeven
Q4 net loss $189M vs $106M loss YoY; FY net loss $391M vs $260M loss.
-
agilon health amends credit agreement, extends maturity to 2028, reduces revolver to $90M
Maturity extended from Feb 2026 to Feb 2028 for $90M revolver (down from $100M).
-
agilon health amends CFO Schwaneke's employment agreement with enhanced equity and severance
One-time award of 600,000 RSUs vesting over three years.
-
agilon health receives NYSE delisting notice; plans reverse stock split
NYSE notified agilon on Nov 5, 2025 that avg closing price was below $1.00 over 30 trading days ended Nov 4, 2025.
-
agilon health Q3 net loss $110M; re-establishes FY2025 guidance with negative EBITDA outlook
Q3 2025 revenue $1.44B, down 1% YoY; net loss $110M vs $118M loss in Q3 2024.
-
CEO Sell resigns; agilon posts $104M Q2 net loss, suspends 2025 guidance
Steven Sell resigned as CEO/President and Board director effective July 29; Board reduced to seven directors.
-
agilon health shareholders approve all proposals at annual meeting
Silvana Battaglia and Sharad Mansukani elected as Class I directors; Battaglia: 367.7M for, Mansukani: 316.0M for.
-
agilon health Q1 2025 revenue $1.53B, net income $12M; reaffirms FY 2025 guidance
Total revenue $1.53B (down 4% YoY); Medicare Advantage members 491,000 (down 6%).
-
Q4 revenue $1.52B (+44% YoY); full-year revenue $6.06B (+40%). Medicare Advantage members 527,000 (+36%).
-
On Dec 4, 2024, agilon health began entering new indemnification agreements with its directors, executive officers, and certain officers, replacing prior agreements.
-
agilon health presents at Wolfe Research Healthcare Conference; details limited
Presentation on Nov 19, 2024 at 2:20 PM ET; webcast replay available on IR site.
-
Medicare Advantage members grew 37% to 525,000; total platform members 657,000 (+39% YoY).
-
agilon health Q2 revenue up 39% to $1.48B but net loss widens to $31M
Revenue $1.48B (+39% YoY); MA membership 513K (+38%).
-
agilon health appoints Jeff Schwaneke as CFO, replacing retiring Tim Bensley effective July 1, 2024
Jeff Schwaneke, former Centene CFO (2016-2021) and EVP Health Care Enterprises, named CFO and EVP effective July 1, 2024.
-
Three Class III directors elected: Ravi Sachdev, Steven J. Sell, William Wulf, M.D., each with over 359M votes for.
-
agilon health Q1 revenue up 52% to $1.6B, net loss $6M; lowers FY2024 member & revenue guidance
Revenue $1.60B (+52% YoY); net loss of $6M vs net income $16M in Q1 2023.
-
Agilon health Q4 net loss $230M, medical margin negative $102M; FY2024 guidance slashed
Q4 revenue $1.06B (+72% YoY) but gross profit of negative $95M vs $16M a year ago.
-
Benjamin Kornitzer, M.D., transitions from CMO to special advisor effective March 1, 2024.
-
agilon health cuts 2023 medical margin guidance by ~$110M; withdraws 2026 outlook
2023 medical margin guidance lowered to $340M-$360M from $455M-$470M, a ~$110M reduction.
-
agilon health CFO Tim Bensley to retire in 2024; search for successor begins
Tim Bensley notified agilon health of his intent to retire as CFO during 2024, expected within nine months.
-
agilon health files slide presentation at Wolfe conference; no new material facts disclosed
Filing contains only an investor slide deck presented at Wolfe Healthcare Conference.
-
Net loss $31M (unchanged YoY); Adj. EBITDA loss $6M vs. $26M loss last year.
-
agilon health CAO Priscilla Kasenchak resigns; Timothy Gertsch succeeds
Chief Accounting Officer Priscilla Kasenchak resigned Aug 11, effective Aug 16, for another opportunity; no disagreement.
-
Revenue $1.15B, +71% YoY; Medicare Advantage members 408,900 (+57%); total members live on platform 495,900.
-
agilon health appoints Silvana Battaglia as independent director; three directors resign
Richard Schnall, Clay Richards, Derek Strum resigned June 22, 2023; no disagreement with company.
-
agilon health stockholders elect four Class II directors, ratify auditor, approve say-on-pay
Ron Williams, Derek Strum, Diana McKenzie, Karen McLoughlin elected as Class II directors with 85-99% support.
-
agilon health selling stockholders to sell 86.9M shares; company to repurchase 9.6M shares
Selling stockholders including CD&R Vector Holdings sell 86,884,353 shares of common stock.
-
agilon health Q1 revenue surges 74% to $1.14B; net income hits $16M
Revenue $1.14B (up 74% YoY); gross profit $77M vs $42M in Q1 2022.
-
Q4 revenue $690M (+49% YoY); FY2022 revenue $2.71B (+48%). Medicare Advantage members 269,500 (+45%).
-
agilon health appoints Diana L. McKenzie to Board of Directors
Appointed as Class II director effective February 17, 2023, term expiring at 2023 annual meeting.
-
agilon health raises 2023 MA membership outlook; guides 2023 Adj. EBITDA $75M-$90M
Reaffirmed 2022 Adjusted EBITDA guidance of $2M to $7M.
-
Director Michelle A. Gourdine resigns from agilon health board effective Dec 19, 2022
Dr. Michelle A. Gourdine resigned from the Board of Directors on December 19, 2022.
-
agilon health Q3 revenue +52% to $695M, medical margin up 74%, raises FY2022 guidance
Revenue $695M (+52% YoY); total platform members 356,000 with 266,600 MA members (+45%).
-
agilon health appoints Priscilla Kasenchak as Chief Accounting Officer
Effective September 30, 2022, Priscilla Kasenchak appointed CAO; previously CAO at Edgewell Personal Care.
-
agilon health appoints Jeffrey Schwaneke to Board, filling vacancy
Michael Smith resigned from the Board effective August 10, 2022, with no disagreement.
-
agilon health Q2 revenue up 34% to $670M, adjusted EBITDA turns positive at $7M
Revenue $670M (+34% YoY); normalized growth 42% excluding prior-year retroactive contract.
-
agilon health shareholders elect four Class I directors at annual meeting
Directors elected: Sharad Mansukani, Clay Richards, Richard Schnall, Michael Smith; each with >355M votes for.
-
agilon health Q1 revenue up 58% to $653M, net income $1M, guides FY2022 revenue $2.5-2.6B
Revenue $653M (+58% YoY); normalized revenue growth 49%. Net income $1M vs $15M loss.
-
agilon health CAO Glenn Sobotka resigns effective May 13, 2022
Glenn Sobotka steps down as Chief Accounting Officer; resignation effective May 13, 2022.
-
Q4 revenue $463M (+44% YoY); FY2021 revenue $1.83B (+50%).
-
agilon health Chief Experience & Innovation Officer Lisa Dombro to resign effective Feb 28, 2022
Lisa Dombro resigns as Chief Experience & Innovation Officer effective February 28, 2022.
-
CBO Theodore Halkias resigns effective Feb 28, 2022 to pursue other opportunity
Theodore Halkias will step down as Chief Business Officer on Feb 28, 2022.
-
agilon health reaffirms 2022 membership guidance and expects positive Adjusted EBITDA
2022 total members expected to exceed 340,000 on agilon platform.
Executive changes
Appointed
Jeff Schwaneke
Chief Financial Officer and Executive Vice President
AGL ·
agilon health, inc.
On June 4, 2024, agilon health, inc. (the “Company”) appointed Jeff Schwaneke to serve as the Company’s Chief Financial Officer and Executive Vice President effective July 1, 2024 (the “Effective Date”).
Appointed
(interim)
Karthik Rao
Interim Chief Medical Officer
AGL ·
agilon health, inc.
Until a successor is named, Dr. Karthik Rao, senior medical director and vice president, network performance, will serve as interim CMO.
Role change
Benjamin Kornitzer, M.D.
Chief Medical Officer
AGL ·
agilon health, inc.
Effective March 1, 2024, Benjamin Kornitzer, M.D., will assume a strategic role as special advisor to agilon health and will transition from his role as chief medical officer (CMO).
Departed
Timothy Bensley
Chief Financial Officer
AGL ·
agilon health, inc.
Timothy Bensley has informed agilon health, inc. (the “Company”) of his intent to retire from his position as Chief Financial Officer (CFO) of the Company during 2024, which the Company expects to take place within the next nine months.
Appointed
Timothy Gertsch
Chief Accounting Officer
AGL ·
agilon health, inc.
Ms. Kasenchak will be succeeded by Timothy Gertsch, agilon heath’s Vice President, Controller, who assumed the role of Chief Accounting Officer on August 16, 2023.
Departed
Priscilla Kasenchak
Chief Accounting Officer
AGL ·
agilon health, inc.
On August 11, 2023, Priscilla Kasenchak, Chief Accounting Officer of agilon health, inc. (“agilon health”), notified agilon health of her decision to resign to pursue another professional opportunity.
Departed
Clay Richards
Director
AGL ·
agilon health, inc.
On June 21, 2023, each of Richard Schnall, Clay Richards and Derek L. Strum tendered letters of resignation from the Board of Directors (the “Board”) of agilon health, inc. (the “Company”), which resignations were effective on June 22, 2023.
Departed
Richard Schnall
Director
AGL ·
agilon health, inc.
On June 21, 2023, each of Richard Schnall, Clay Richards and Derek L. Strum tendered letters of resignation from the Board of Directors (the “Board”) of agilon health, inc. (the “Company”), which resignations were effective on June 22, 2023.
Appointed
Silvana Battaglia
Director
AGL ·
agilon health, inc.
On June 22, 2023, the Board, upon the recommendation of the Nominating and Governance Committee, appointed Silvana Battaglia as an independent Class I Director in accordance with the Company’s Amended and Restated Certificate of Incorporation, to fill the vacancy on the Board created by Mr. Richard’s resignation from the Board.
Departed
Derek L. Strum
Director
AGL ·
agilon health, inc.
On June 21, 2023, each of Richard Schnall, Clay Richards and Derek L. Strum tendered letters of resignation from the Board of Directors (the “Board”) of agilon health, inc. (the “Company”), which resignations were effective on June 22, 2023.
Appointed
Diana L. McKenzie
Class II director
AGL ·
agilon health, inc.
Effective February 17, 2023, to fill a vacancy on the Board of Directors, Diana L. McKenzie was appointed to the Board as a Class II director in accordance with the Amended and Restated Certificate of Incorporation of agilon health, inc.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.65 · Most common event earnings